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Supplementary Tables 
Table S1. SCAR16 patient variables. 
 
ID HZ Genotype Mut1 Mut2 Ex1 Ex2 AA1 AA2 Sex AOO (y) Ancestry SARA HG CD TR 
1_04 N c.82G>A c.430A>T E28K K144* 1 3 28 144 F 33 SAS 23‡ Y Y N 
1_01 Y c.194A>G N65S N/A 2 N/A 65 N/A M 2 MENA 29‡ N Y Y 
1_02 Y c.194A>G N65S N/A 2 N/A 65 N/A M 0.01 MENA 29‡ N Y Y 
1_03 Y c.194A>G N65S N/A 2 N/A 65 N/A F 0.7 MENA 11‡ N Y Y 
2_03 N c.235G>A c.236C>A A79T A79D 2 2 79 79 M 49 MENA 14.5 N N Y 
2_04 N c.235G>A c.236C>A A79T A79D 2 2 79 79 M 29 MENA 14.5† N N Y 
3_01 N c.335C>T c.880A>T R119* I294F 2 7 119 294 M 12 EUR 36 Y Y Y 
2_01 Y c.367C>G L123V N/A 3 N/A 123 N/A M 2 EUR 10 N N N 
4_05 N c.389A>T c.441G>T N130I W147C 3 3 130 147 M 20 EAS 4 N N N 
5_01 N c.433A>C c.687-690delCTAC K145Q Y230Cfx*8 3 6 145 N/A M 23 EUR 20† N Y Y 
5_02 N c.433A>C c.687-690delCTAC K145Q Y230Cfx*8 3 6 145 N/A M 25 EUR 20† N Y Y 
3_02 N c.433A>C c.728C>T K145Q P243L 3 6 145 243 M 12 EUR 40 N Y Y 
3_03 N c.433A>C c.728C>T K145Q P243L 3 6 145 243 F 20 EUR 40 N Y Y 
4_01 Y c.493C>T L165F N/A 3 N/A 165 N/A F 17 EAS 34 N Y N 
4_02 Y c.493C>T L165F N/A 3 N/A 165 N/A F 17 EAS 15 N N Y 
4_03 Y c.493C>T L165F N/A 3 N/A 165 N/A F 14 EAS 21 N Y Y 
4_04 Y c.493C>T L165F N/A 3 N/A 165 N/A M 19 EAS 15 N N Y 
4_06 N c.621C>G c.707G>C Y207X S236T 5 6 207 236 F 16 EAS 5 N N Y 
6_01 N c.633G>A c.712G>T M211I E238* 5 6 211 238 F 25 EUR 34† N Y Y 
6_02 N c.633G>A c.712G>T M211I E238* 5 6 211 238 M 22 EUR 30† N Y Y 
2_02 Y  c.719T>C M240T N/A 6 N/A 240 N/A F 16 MENA 12 N Y N 
7_01 Y c.737C>T T246M N/A 6 N/A 246 N/A F 19 EAS 13 Y Y N 
7_02 Y c.737C>T T246M N/A 6 N/A 246 N/A F 17 EAS 15 Y Y Y 
8_01 N c.612+1G>C c.823C>G syn L275V i 4-5 7 N/A 275 M 15 AMR 17 N Y Y 
ID is unique identifier comprised of the referenced study (see Supplementary References) and a number in the format ref_##, HZ = homozygous mutation, Mut = 
mutation, Ex = exon, AA = amino acid, AOO = age of onset, AMR = Admixed American, SAS = South Asian, MENA = Middle Eastern North African, EUR = European, 
EAS = East Asian, SARA = scale for the assessment and rating of ataxia, HG = hypogonadism, CD = cognitive dysfunction, TR = increased tendon reflex, Syn = 
synonymous mutation, N/A = not applicable. 
a imputed from the clinical report 
b calculated from Disability Scale 
c imputed from clinical report 
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Supplementary Tables (cont.) 
Table S2. Bivariate analysis of AOO and SARA with SCAR16 patient phenotypes. 
 
 SARA AOO 
Variable Statistic P Q Statistic P Q 
Cognitive dysfunction (yes) 13.8 0.002 0.011 -5.67 0.252 0.756 
Ancestry (MENA, EUR, EAS) 4.13a 0.032 0.097 0.03a 0.735 0.999 
Increased tendon reflex (yes) 6.56 0.199 0.398 -0.18 0.972 0.999 
Homozygosity (yes) -4.38 0.328 0.491 -11.9 0.005 0.027 
AOO (year) -0.08b 0.721 0.792  N/A  
Sex (male) 1.19 0.792 0.792 -0.01 0.999 0.999 
SARA  N/A  -0.08b 0.721 0.999 
Student’s t tests were used to calculate the difference (statistic), P, and Q values between scale for the assessment and rating of 
ataxia (SARA) or age of onset (AOO) and each variable, unless otherwise indicated. Super populations for ancestry: MENA 
= Middle Eastern North African, EUR = European, EAS = East Asian. 
aANOVA was used and the F ratio is provided as the statistic 
bLinear regression was used and the beta is provided as the statistic 
Table S3. Biochemical properties of mutant CHIP proteins. 
 
Mut AA# Ex Domain Oligomer Tm %E %Ub chain %HSP70 Ub KD Bmax 
WT N/A N/A N/A dimer 39.0 100 100 73 2.9 203.6 
E28K 28 1 TPR oligomer 35.4 50 120 46 10.1 204.8 
N65S 65 2 TPR dimer 39.0 40 25 42 N/A N/A 
A79T 79 2 TPR dimer 37.5 60 120 47 3.9 192.4 
A79D 79 2 TPR oligomer 31.4 25 110 47 9.2 188.2 
L123V 123 3 TPR oligomer 32.1 40 75 46 N/A N/A 
N130I 130 3 CC dimer 37.6 0 90 47 16.2 215.9 
K145Q 145 3 CC dimer 36.7 0 95 49 3.9 202.7 
W147C 147 3 CC oligomer 37.2 90 90 45 3.3 216.7 
L165F 165 3 CC dimer 36.7 10 95 57 3.9 207 
M211I 211 5 CC dimer 41.1 90 100 63 2.5 206.7 
S236T 236 6 Ubox dimer 38.2 80 25 49 4.3 214.5 
M240T 240 6 Ubox oligomer 41.1 60 15 25 17.5 243.7 
T246M 246 6 Ubox oligomer 27.1 15 15 7 17.8 238.6 
AA = amino acid, Tm = thermal melting temperature (℃), %E = percentage of steady-state protein expression relative to 
wild-type (WT) CHIP, %Ub chain = percentage of E2-mediated ubiquitin chain formation relative to CHIP-WT, %HSP70 
Ub = percentage of HSP70 that was modified by ubiquitination, KD = equilibrium dissociation constant (μM), Bmax = amount 
of HSP70 binding (μmol•min-1). TPR = tetratricopeptide repeat, CC = coiled-coil, Ubox = U-box domain containing. N/A = 
saturation not reached.  
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Table S4. Multivariate analysis of CHIP biochemical properties. 
 
Variable 1 Variable 2 r P Q 
Bmax %Ub chain -0.856 0.0004 0.006 
KD %HSP70 Ub -0.760 0.0042 0.032 
%HSP70 Ub %Ub chain 0.641 0.0135 0.068 
Bmax %HSP70 Ub -0.678 0.0154 0.058 
Bmax KD 0.658 0.0199 0.060 
%HSP70 Ub Tm 0.521 0.0559 0.140 
%E Tm 0.488 0.0770 0.165 
KD %Ub chain -0.521 0.0824 0.155 
KD %E -0.445 0.1468 0.245 
%HSP70 Ub %E 0.380 0.1801 0.270 
KD Tm -0.312 0.3231 0.441 
%Ub chain Tm 0.055 0.8511 1.000 
Bmax Tm 0.045 0.8898 1.000 
Bmax %E -0.031 0.9227 1.000 
%Ub chain %E 0.026 0.9309 1.000 
The Pearson correlation coefficient (r), P, and Q values of the pair-wise comparisons of biochemical properties of CHIP 
proteins. Bmax = amount of binding, KD = equilibrium dissociation constant, Tm = thermal melting temperature, %Ub chain = 
E2-dependent ubiquitin chain formation, %E = steady-state expression levels relative to wild-type CHIP, %HSP70 Ub = 
amount of ubiquitinated HSP70 relative to wild-type CHIP.  
Table S5. Analysis of SCAR16 mutation location with biochemical properties of the encoded mutant CHIP protein 
 
Biochemical property F ratio P Q 
%Ub chain  9.3 0.0053 0.0165 
Bmax 10.7 0.0055 0.0165 
%HSP70 Ub 5.2 0.0281 0.0562 
KD 1.5 0.2871 0.4307 
Tm 0.6 0.5430 0.6516 
%E 0.1 0.8658 0.8358 
The F ratio, P, and Q values of from ANOVA testing of the three domains of CHIP with the variance in 
biochemical properties. Bmax = amount of binding, KD = equilibrium dissociation constant. Tm = thermal melting 
temperature, %Ub chain = E2-dependent ubiquitin chain formation, %E = steady-state expression levels relative 
to wild-type CHIP, HSP70 Ub = amount of ubiquitinated HSP70 relative to wild-type CHIP.  
Table S6. Analysis of cognitive dysfunction and increased tendon reflex with biochemical properties of CHIP. 
 
 CD   TR   
Variable Statistic P Q Statistic P Q 
%Ub chain -34.5 0.0086 0.060 9.0 0.5328 0.622 
Bmax 14.3 0.0232 0.081 -17.7 0.0058 0.020 
%HSP70 Ub -9.51 0.0772 0.180 9.87 0.0787 0.138 
KD 3.01 0.2003 0.351 -6.21 0.0079 0.020 
Tm 0.82 0.5666 0.678 1.61 0.2756 0.386 
%E -5.39 0.5811 0.678 -5.06 0.6195 0.620 
Oligomeric (yes)   0.7160a 0.716  0.0018a 0.013 
Student’s t tests were used to calculate the difference (statistic), P, and Q values between cognitive dysfunction (CD) or 
increased tendon reflex (TR) and each variable, unless otherwise indicated.  
aFisher’s Exact Test (2-tailed) 
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Table S7. Analysis AOO and SARA with biochemical properties of CHIP. 
 
 SARA   AOO    
Variable Statistic P Q Statistic P Q  
%Ub chain 0.046 0.2865 0.334 0.182 0.0001 0.001  
Bmax -0.190 0.1014 0.178 -0.286 0.0044 0.016  
KD -0.715 0.0228 0.080 -0.148 0.6203 0.740  
Oligomeric (yes) -9.083a 0.0070 0.049 4.066a 0.3372 0.740  
%HSP70 Ub 0.204 0.0559 0.130 0.071 0.5862 0.821  
Tm 0.665 0.1081 0.178 -0.503 0.3170 0.821  
%E -0.056 0.3643 0.364 0.020 0.7916 0.821  
Linear regression was used to calculate the beta (statistic), P, and Q values between SARA or age of onset (AOO) with the 
indicated variables, unless otherwise indicated. Variables that were included in the regression modeling are indicated as well 
as the beta coefficients from the initial fit. SARA = Scale for the Assessment and Rating of Ataxia, Bmax = amount of HSP70 
binding, KD = equilibrium dissociation constant. Tm = thermal melting temperature. 




Figure S1. Regression model performance of age of onset and SARA as a function of the biochemical properties of mutant CHIP 
proteins.  
(A) Scatter plot of actual age of onset (AOO) by predicted onset (AOOadj) via the PLS model. (B) Scatter plot of actual SARA 
(Scale for the Assessment and Rating of Ataxia) by predicted SARA (SARAadj2) plot of the PLS model. The mean values of the 
adjusted (y-axis) and actual (x-axis) are indicated by the red tick marks. 
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